Pharsight

Soolantra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033565 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(24 days from now)

US8815816 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(24 days from now)

US8093219 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(24 days from now)

US8080530 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(24 days from now)

US8415311 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(24 days from now)

US8470788 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(24 days from now)

US7550440 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(24 days from now)

US9233118 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(9 years from now)

US10206939 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(9 years from now)

US9089587 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(9 years from now)

US9233117 GALDERMA LABS LP Treatment of inflammatory lesions of rosacea with ivermectin
Mar, 2034

(9 years from now)

US9782425 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(9 years from now)

Soolantra is owned by Galderma Labs Lp.

Soolantra contains Ivermectin.

Soolantra has a total of 12 drug patents out of which 0 drug patents have expired.

Soolantra was authorised for market use on 19 December, 2014.

Soolantra is available in cream;topical dosage forms.

Soolantra can be used as treatment of inflammatory lesions of rosacea..

The generics of Soolantra are possible to be released after 13 March, 2034.

Drugs and Companies using IVERMECTIN ingredient

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of inflammatory lesions of rosacea.

Dosage: CREAM;TOPICAL

How can I launch a generic of SOOLANTRA before it's drug patent expiration?
More Information on Dosage

SOOLANTRA family patents

Family Patents